Westfield Capital Management Co. LP Has $40.31 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)

Westfield Capital Management Co. LP trimmed its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 331,270 shares of the biopharmaceutical company’s stock after selling 27,942 shares during the period. Westfield Capital Management Co. LP owned about 0.15% of Alexion Pharmaceuticals worth $40,306,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ALXN. BlackRock Inc. grew its holdings in Alexion Pharmaceuticals by 2,689.8% during the 1st quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after purchasing an additional 17,960,356 shares during the last quarter. Bank of Montreal Can grew its holdings in Alexion Pharmaceuticals by 628.8% during the 2nd quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock valued at $173,174,000 after purchasing an additional 1,228,025 shares during the last quarter. TIAA CREF Investment Management LLC grew its holdings in Alexion Pharmaceuticals by 42.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock valued at $391,773,000 after purchasing an additional 955,578 shares during the last quarter. Bessemer Group Inc. grew its holdings in Alexion Pharmaceuticals by 1,949,640.5% during the 2nd quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock valued at $87,772,000 after purchasing an additional 721,367 shares during the last quarter. Finally, State Street Corp grew its holdings in Alexion Pharmaceuticals by 6.8% during the 1st quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after purchasing an additional 718,756 shares during the last quarter. Institutional investors own 94.26% of the company’s stock.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock valued at $2,416,869 in the last quarter. 4.35% of the stock is currently owned by company insiders.

ALXN has been the topic of several analyst reports. BMO Capital Markets reiterated an “outperform” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $142.00 price target on shares of Alexion Pharmaceuticals in a report on Friday, June 9th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target on the stock in a report on Wednesday, August 2nd. Leerink Swann reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Tuesday, May 23rd. Finally, Oppenheimer Holdings, Inc. upgraded shares of Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price target on the stock in a report on Friday, July 28th. Five equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and three have given a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $157.13.

TRADEMARK VIOLATION NOTICE: “Westfield Capital Management Co. LP Has $40.31 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://transcriptdaily.com/2017/09/17/westfield-capital-management-co-lp-has-40-31-million-position-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up 1.44% during midday trading on Friday, reaching $146.69. 3,713,613 shares of the company were exchanged. The firm has a 50-day moving average price of $138.83 and a 200-day moving average price of $124.75. The company has a market capitalization of $32.74 billion, a PE ratio of 63.61 and a beta of 1.40. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912.00 million during the quarter, compared to analysts’ expectations of $846.15 million. During the same quarter in the previous year, the business posted $1.13 earnings per share. The business’s quarterly revenue was up 21.1% compared to the same quarter last year. Equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.62 earnings per share for the current fiscal year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply